AAX Biotech secures investment from Trio Impact Invest
Karolinska spin-off receives funding to expand proprietary antibody technologies
Advertisement
Biotech company AAX Biotech announced that Trio Impact Invest AB has invested in AAX Biotech. The investment supports the continued development and scaling of the company’s antibody technology platforms, enabling expanded application areas and strengthened industry collaborations.
Daniel X Johansson, CEO and CSO of AAX Biotech (left), and Siimon Vaske, CEO of Trio Impact Invest AB (right).
AAX Biotech AB
AAX Biotech develops proprietary technologies, including Seqitope® and Opti-mAb®, designed to advance antibody discovery, optimization and developability across modern therapeutic formats. Through these platforms, the company collaborates with partners across antibody discovery and engineering, delivering advanced solutions that enhance antibody performance and support clinical success.
The investment follows a period of technological and commercial progress at AAX Biotech, including the implementation of advanced automation to enhance platform scalability and several new collaborations, among them one with global pharmaceutical company Daiichi Sankyo.
Trio Impact Invest’s investment will be allocated to platform advancement and continued development of industry partnerships.
“This investment marks the next phase of platform development and expansion,” said Daniel X Johansson, CEO and CSO of AAX Biotech. “With Trio Impact Invest’s support, we can scale our proprietary platforms, broaden their impact across antibody discovery and development, and strengthen collaborations with new and existing partners.”
Trio Impact Invest is a Swedish deep tech venture capital firm investing in early-stage, research-intensive companies with the potential for significant societal and commercial impact. Trio Impact Invest focuses on enabling technologies and long-term value creation through active ownership and close collaboration with founders.
“We’re thrilled to make our first investment from Trio Impact Invest in AAX Biotech, backing a team whose enabling technology can meaningfully improve how antibody-based medicines are discovered and optimized,” said Siimon Vaske, CEO of Trio Impact Invest AB. “AAX combines strong scientific capability with a clear roadmap to scale its proprietary platform and drive impact through collaborations and continued technology development.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous